Research Triangle Park, N.C. — In a move set to reshape the future of oncology research, IQVIA and Sarah Cannon Research Institute’s (SCRI) clinical research division, SCRI Development Innovations, have announced a strategic collaboration aimed at streamlining and accelerating cancer clinical trials worldwide.
The partnership combines IQVIA’s global trial management expertise—which includes oversight of one in five oncology trials in the U.S.—with SCRI’s Accelero model, a cutting-edge operational framework designed to reduce trial activation time and improve patient recruitment. The result is a robust, integrated platform that promises faster data delivery, greater efficiency, and earlier access to life-saving therapies for cancer patients.
“This collaboration reflects our commitment to simplifying complex processes and improving outcomes for patients globally,” said Richard Staub, President of Research & Development Solutions at IQVIA. “By integrating IQVIA’s global scale and advanced data capabilities with SCRI’s community oncology focus and operational excellence, we’re creating a powerful delivery model for biopharma sponsors.”
SCRI’s Accelero model streamlines clinical trial processes by integrating data from electronic health records (EHR) directly into electronic data capture (EDC) systems, reducing redundancies and improving accuracy. The model also reduces administrative burdens on research sites and boosts participant enrollment, particularly within the U.S. community oncology landscape.
“Partnering with IQVIA enables us to expand our impact on a global scale,” said Dee Anna Smith, CEO of Sarah Cannon Research Institute. “Through Accelero and IQVIA’s reach in trial design and patient recruitment, we can deliver more efficient, technology-driven solutions that bring promising treatments to patients faster than ever before.”
This collaboration comes as biopharma companies increasingly seek streamlined, integrated trial models that minimize delays and maximize patient access to next-generation therapies. By uniting their complementary strengths, IQVIA and SCRI aim to serve as a model for global oncology trial delivery.
The partnership will be featured at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago. Attendees can visit IQVIA at Booth 14103 and SCRI at Booth 27022 to learn more about how the collaboration is advancing cancer research and clinical trial innovation.
